170 related articles for article (PubMed ID: 20072155)
1. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.
Foster AE; Okur FV; Biagi E; Lu A; Dotti G; Yvon E; Savoldo B; Carrum G; Goodell MA; Heslop HE; Brenner MK
Leukemia; 2010 Mar; 24(3):563-72. PubMed ID: 20072155
[TBL] [Abstract][Full Text] [Related]
2. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
3. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells.
Biagi E; Yvon E; Dotti G; Amrolia PJ; Takahashi S; Popat U; Marini F; Andreeff M; Brenner MK; Rousseau RF
Hum Gene Ther; 2003 Apr; 14(6):545-59. PubMed ID: 12718765
[TBL] [Abstract][Full Text] [Related]
4. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.
Biagi E; Dotti G; Yvon E; Lee E; Pule M; Vigouroux S; Gottschalk S; Popat U; Rousseau R; Brenner M
Blood; 2005 Mar; 105(6):2436-42. PubMed ID: 15536147
[TBL] [Abstract][Full Text] [Related]
5. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
[TBL] [Abstract][Full Text] [Related]
7. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.
Giannopoulos K; Mertens D; Bühler A; Barth TF; Idler I; Möller P; Kröber A; Greiner J; Chocholska S; Dmoszyñska A; Roliñski J; Döhner H; Stilgenbauer S; Schmitt M
Leukemia; 2009 Mar; 23(3):519-27. PubMed ID: 19092852
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
9. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
10. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
[TBL] [Abstract][Full Text] [Related]
11. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
Biagi E; Rousseau R; Yvon E; Schwartz M; Dotti G; Foster A; Havlik-Cooper D; Grilley B; Gee A; Baker K; Carrum G; Rice L; Andreeff M; Popat U; Brenner M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6916-23. PubMed ID: 16203783
[TBL] [Abstract][Full Text] [Related]
12. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
Tabarkiewicz J; Giannopoulos K
Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
[TBL] [Abstract][Full Text] [Related]
13. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.
Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R
J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.
Okur FV; Yvon E; Biagi E; Dotti G; Carrum G; Heslop H; Mims MP; Fratantoni JC; Peshwa MV; Li L; Brenner MK
Cytotherapy; 2011 Oct; 13(9):1128-39. PubMed ID: 21745159
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Petersen AJ; Brown RD; Gibson J; Pope B; Luo XF; Schutz L; Wiley JS; Joshua DE
Eur J Haematol; 1996 Apr; 56(4):213-20. PubMed ID: 8641389
[TBL] [Abstract][Full Text] [Related]
16. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
[TBL] [Abstract][Full Text] [Related]
17. TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia.
Szymańska A; Bojarska-Junak A; Drobiecki A; Tomczak W; Roliński J; Hus M; Hus I
Arch Immunol Ther Exp (Warsz); 2019 Feb; 67(1):55-65. PubMed ID: 30196472
[TBL] [Abstract][Full Text] [Related]
18. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
Martinez-Lostao L; Briones J; Martinez-Gallo M; Forné I; Sierra J; Rodriguez-Sanchez JL; Juarez C
Leuk Lymphoma; 2004 Nov; 45(11):2307-14. PubMed ID: 15512822
[TBL] [Abstract][Full Text] [Related]
20. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Palena C; Foon KA; Panicali D; Yafal AG; Chinsangaram J; Hodge JW; Schlom J; Tsang KY
Blood; 2005 Nov; 106(10):3515-23. PubMed ID: 16081691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
